Last reviewed · How we verify

Shanghai Shengdi Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief

Shanghai Shengdi Pharmaceutical Co., Ltd pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Gadobutrol Injection Gadobutrol Injection phase 3 Gadolinium-based contrast agent Water protons (paramagnetic enhancement) Diagnostic Imaging

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bayer · 1 shared drug class
  2. Bracco Diagnostics, Inc · 1 shared drug class
  3. GE Healthcare · 1 shared drug class
  4. Guerbet · 1 shared drug class
  5. Paracelsus Medical University · 1 shared drug class
  6. Seoul National University Hospital · 1 shared drug class
  7. The Central Hospital of Lishui City · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shanghai Shengdi Pharmaceutical Co., Ltd:

Cite this brief

Drug Landscape (2026). Shanghai Shengdi Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-shengdi-pharmaceutical-co-ltd. Accessed 2026-05-17.

Related